NOVAVAX INC Revenue by Geography
No Revenue by Geography for NVAX on this site yet.
- 2025-12-31: Others Not split by product in the filing$1.12B100.00%; Total revenue $1.12B.
- 2024-12-31: Others Not split by product in the filing$682.16M100.00%; Total revenue $682.16M.
- 2023-12-31: Others Not split by product in the filing$983.71M100.00%; Total revenue $983.71M.
- 2022-12-31: Others Not split by product in the filing$1.98B100.00%; Total revenue $1.98B.
Source checked: the stored Revenue by Geography page for NVAX.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product in the filing $1.12B 100.00% | $1.12B |
| 2024-12-31 | Not split by product in the filing $682.16M 100.00% | $682.16M |
| 2023-12-31 | Not split by product in the filing $983.71M 100.00% | $983.71M |
| 2022-12-31 | Not split by product in the filing $1.98B 100.00% | $1.98B |
| 2021-12-31 | Not split by product in the filing $1.15B 100.00% | $1.15B |
| 2020-12-31 | Not split by product in the filing $475.60M 100.00% | $475.60M |
| 2019-12-31 | Not split by product in the filing $18.66M 100.00% | $18.66M |
| 2018-12-31 | Not split by product in the filing $34.29M 100.00% | $34.29M |
| 2017-12-31 | Not split by product in the filing $31.18M 100.00% | $31.18M |
| 2016-12-31 | Not split by product in the filing $15.35M 100.00% | $15.35M |
| 2015-12-31 | Not split by product in the filing $36.25M 100.00% | $36.25M |
| 2014-12-31 | Not split by product in the filing $30.66M 100.00% | $30.66M |
| 2013-12-31 | Not split by product in the filing $20.91M 100.00% | $20.91M |
| 2012-12-31 | Not split by product in the filing $22.08M 100.00% | $22.08M |
| 2011-12-31 | Not split by product in the filing $14.69M 100.00% | $14.69M |
| 2010-12-31 | $343.00K |
Each quarter (3 month)
| Quarter end | Licensing, Royalties, and Other | Supply Sales | Others | Total revenue |
|---|---|---|---|---|
| 2026-06-30 | $37.84M 66.75% | $18.85M 33.25% | $56.70M | |
| 2026-03-31 | Not split by product $139.51M 100.00% | $139.51M | ||
| 2025-12-31 | Not split by product $147.14M 100.00% | $147.14M | ||
| 2025-09-30 | Not split by product $70.44M 100.00% | $70.44M | ||
| 2025-06-30 | $228.52M 95.52% | $12.82M 5.36% | Not split by product in the filing -$2.09M -0.87% | $239.24M |
| 2025-03-31 | Not split by product $666.65M 100.00% | $666.65M | ||
| 2024-12-31 | Not split by product $88.31M 100.00% | $88.31M | ||
| 2024-09-30 | Not split by product $84.51M 100.00% | $84.51M | ||
| 2024-06-30 | Not split by product $415.48M 100.00% | $415.48M | ||
| 2024-03-31 | Not split by product $93.86M 100.00% | $93.86M | ||
| 2023-12-31 | Not split by product $291.34M 100.00% | $291.34M | ||
| 2023-09-30 | Not split by product $186.99M 100.00% | $186.99M | ||
| 2023-06-30 | Not split by product $424.43M 100.00% | $424.43M | ||
| 2023-03-31 | Not split by product $80.95M 100.00% | $80.95M | ||
| 2022-12-31 | Not split by product $357.40M 100.00% | $357.40M | ||
| 2022-09-30 | Not split by product $734.58M 100.00% | $734.58M | ||
| 2022-06-30 | Not split by product $185.93M 100.00% | $185.93M | ||
| 2022-03-31 | Not split by product $703.97M 100.00% | $703.97M | ||
| 2021-12-31 | Not split by product $222.20M 100.00% | $222.20M | ||
| 2021-09-30 | Not split by product $178.84M 100.00% | $178.84M | ||
| 2021-06-30 | Not split by product $298.02M 100.00% | $298.02M | ||
| 2021-03-31 | Not split by product $447.23M 100.00% | $447.23M | ||
| 2020-12-31 | Not split by product $279.66M 100.00% | $279.66M | ||
| 2020-09-30 | Not split by product $157.02M 100.00% | $157.02M | ||
| 2020-06-30 | Not split by product $35.54M 100.00% | $35.54M | ||
| 2020-03-31 | Not split by product $3.38M 100.00% | $3.38M | ||
| 2019-12-31 | Not split by product $8.82M 100.00% | $8.82M | ||
| 2019-09-30 | Not split by product $2.51M 100.00% | $2.51M | ||
| 2019-06-30 | Not split by product $3.36M 100.00% | $3.36M | ||
| 2019-03-31 | Not split by product $3.98M 100.00% | $3.98M | ||
| 2018-12-31 | Not split by product $6.13M 100.00% | $6.13M | ||
| 2018-09-30 | Not split by product $7.74M 100.00% | $7.74M | ||
| 2018-06-30 | Not split by product $10.77M 100.00% | $10.77M | ||
| 2018-03-31 | Not split by product $9.65M 100.00% | $9.65M | ||
| 2017-12-31 | Not split by product $10.41M 100.00% | $10.41M | ||
| 2017-09-30 | Not split by product $8.35M 100.00% | $8.35M | ||
| 2017-06-30 | Not split by product $6.73M 100.00% | $6.73M | ||
| 2017-03-31 | Not split by product $5.68M 100.00% | $5.68M | ||
| 2016-12-31 | Not split by product $5.40M 100.00% | $5.40M | ||
| 2016-09-30 | Not split by product $3.23M 100.00% | $3.23M | ||
| 2016-06-30 | Not split by product $2.50M 100.00% | $2.50M | ||
| 2016-03-31 | Not split by product $4.22M 100.00% | $4.22M | ||
| 2015-12-31 | Not split by product $5.85M 100.00% | $5.85M | ||
| 2015-09-30 | Not split by product $6.53M 100.00% | $6.53M | ||
| 2015-06-30 | Not split by product $14.00M 100.00% | $14.00M | ||
| 2015-03-31 | Not split by product $9.88M 100.00% | $9.88M | ||
| 2014-12-31 | Not split by product $6.72M 100.00% | $6.72M | ||
| 2014-09-30 | Not split by product $8.21M 100.00% | $8.21M | ||
| 2014-06-30 | Not split by product $8.26M 100.00% | $8.26M | ||
| 2014-03-31 | Not split by product $7.46M 100.00% | $7.46M | ||
| 2013-12-31 | Not split by product $8.75M 100.00% | $8.75M | ||
| 2013-09-30 | Not split by product $4.80M 100.00% | $4.80M | ||
| 2013-06-30 | Not split by product $3.53M 100.00% | $3.53M | ||
| 2013-03-31 | Not split by product $3.83M 100.00% | $3.83M | ||
| 2012-12-31 | Not split by product $4.57M 100.00% | $4.57M | ||
| 2012-09-30 | Not split by product $5.76M 100.00% | $5.76M | ||
| 2012-06-30 | Not split by product $7.10M 100.00% | $7.10M | ||
| 2012-03-31 | Not split by product $4.64M 100.00% | $4.64M | ||
| 2011-12-31 | Not split by product $5.84M 100.00% | $5.84M | ||
| 2011-09-30 | Not split by product $5.01M 100.00% | $5.01M | ||
| 2011-06-30 | Not split by product $3.00M 100.00% | $3.00M | ||
| 2011-03-31 | Not split by product $834.00K 100.00% | $834.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |